Targeted Oncology

Published by: Springer  

People

  1. Motzer
    Motzer
  2. Abou-Alfa
    Abou-Alfa
  3. Trippett
    Trippett
  4. Baum
    Baum
  5. Diaz
    Diaz
  6. Harding
    Harding
  7. Kelly
    Kelly
  8. Paik
    Paik
  9. Pfister
    Pfister
  10. Rousseau
    Rousseau

Groups

  1. Department of Medicine (12)
  2. Solid Tumor Oncology Division (11)
  3. Center for Hematologic Malignancies (3)
  4. Gastrointestinal Oncology Service (3)
  5. Genitourinary Oncology Service (3)
  6. Hematologic Malignancies Service (2)
  7. Pediatric Leukemia (2)
  8. Pediatrics, Department of (2)
  9. Thoracic Oncology (2)
  10. Breast Medicine Service (1)
Search Within
Formats
  1. Journal Article (18)
  2. Review (2)
Groups
  1. Department of Medicine (12)
  2. Solid Tumor Oncology Division (11)
  3. Center for Hematologic Malignancies (3)
  4. Gastrointestinal Oncology Service (3)
  5. Genitourinary Oncology Service (3)
  6. Hematologic Malignancies Service (2)

More Groups

People
  1. Robert Motzer (3)
  2. Ghassan Abou-Alfa (2)
  3. Robert Maki (2)
  4. Tanya Trippett (2)
  5. Amin Yaqubie (1)
  6. Andrew Lassman (1)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (4)
  4. 2022 (2)
  5. 2020 (1)
  6. 2018 (1)

More Years

Publishers
  1. Springer (20)

Results (20)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • IDH1/2 mutations in cancer: Unifying insights and unlocking therapeutic potential for chondrosarcoma
    Review

    Deshmukh, S.; Kelly, C.; Tinoco, G.
    Targeted Oncology (2025)

    Fulltext@MSK | Save
  • Adavosertib in combination with olaparib in patients with refractory solid tumors: An open-label, dose-finding, and dose-expansion Phase Ib trial
    Journal Article

    Hamilton, E. P.; Falchook, G. S.; Wang, J. S.; Fu, S.; Oza, A. M.; Imedio, E. R.; Kumar, S.; Ottesen, L.; Mugundu, G. M.; de Bruin, E. C.; more...
    Targeted Oncology (2024)

    Fulltext@MSK | Save
  • ASCT2-targeting antibody-drug conjugate medi7247 in adult patients with relapsed/refractory hematological malignancies: A first-in-human, phase 1 study
    Journal Article

    Maris, M.; Salles, G.; Kim, W. S.; Kim, T. M.; Lyons, R. M.; Arellano, M.; Karmali, R.; Schiller, G.; Cull, E.; Abboud, C. N.; more...
    Targeted Oncology (2024)

    Fulltext@MSK | Save
  • Modelling the effectiveness of tepotinib in comparison to standard-of-care treatments in patients with advanced non-small cell lung cancer (NSCLC) harbouring METex14 skipping in the UK
    Journal Article

    Batteson, R.; Hook, E.; Wheat, H.; Hatswell, A. J.; Vioix, H.; McLean, T.; Alexopoulos, S. T.; Baijal, S.; Paik, P. K.
    Targeted Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1b/2 study of alpelisib in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma
    Journal Article

    Razak, A. R. A.; Wang, H. M.; Chang, J. Y.; Ahn, M. J.; Munster, P.; Blumenschein, G.; Solomon, B.; Lim, D. W. T.; Hong, R. L.; Pfister, D.; more...
    Targeted Oncology (2023)

    Fulltext@MSK | Save
  • Population pharmacokinetics and exposure–response with teclistamab in patients with relapsed/refractory multiple myeloma: Results from MajesTEC-1
    Journal Article

    Miao, X.; Wu, L. S.; Lin, S. X. W.; Xu, Y.; Chen, Y.; Iwaki, Y.; Kobos, R.; Stephenson, T.; Kemmerer, K.; Uhlar, C. M.; more...
    Targeted Oncology (2023)

    Fulltext@MSK | Save
  • Summary of research: Adjuvant nivolumab plus ipilimumab versus placebo for localized renal cell carcinoma after nephrectomy (CheckMate 914): A double-blind, randomized, phase 3 trial
    Journal Article

    Motzer, R. J.; Russo, P.; Grünwald, V.; Tomita, Y.; Zurawski, B.; Parikh, O.; Buti, S.; Barthélémy, P.; Goh, J. C.; Ye, D.; more...
    Targeted Oncology (2023)

    Fulltext@MSK | Save
  • First-in-human study of INCB062079, a fibroblast growth factor receptor 4 inhibitor, in patients with advanced solid tumors
    Journal Article

    Harding, J. J.; Jungels, C.; Machiels, J. P.; Smith, D. C.; Walker, C.; Ji, T.; Jiang, P.; Li, X.; Asatiani, E.; Van Cutsem, E.; more...
    Targeted Oncology (2023)

    Fulltext@MSK | Save
  • Effect of FGFR2 alterations on overall and progression-free survival in patients receiving systemic therapy for intrahepatic cholangiocarcinoma
    Journal Article

    Abou-Alfa, G. K.; Bibeau, K.; Schultz, N.; Yaqubie, A.; Millang, B.; Ren, H.; Féliz, L.
    Targeted Oncology (2022)

    Fulltext@MSK | Save
  • Cobimetinib in pediatric and young adult patients with relapsed or refractory solid tumors (iMatrix-cobi): A multicenter, phase I/II study
    Journal Article

    Trippett, T.; Toledano, H.; Campbell Hewson, Q.; Verschuur, A.; Langevin, A. M.; Aerts, I.; Howell, L.; Gallego, S.; Rossig, C.; Smith, A.; more...
    Targeted Oncology (2022)

    Fulltext@MSK | Save

    • Targeted Oncology – authorized name for:

    Name ISSN / ISBN Publisher
    Targeted Oncology 1776-2596 Springer
    Targeted Oncology 17762596 2018, Springer Nature Switzerland Ag
    Targeted Oncology 17762596 2023, The Author(s)
    Targeted Oncology 17762596 Springer Verlag
    Targeted Oncology 1776-2596 Unknown
    Targeted Oncology 1776-2596 Springer
    Targeted Oncology 17762596 Springer Verlag
    Targeted Oncology 17762596 2014, The Author(s)
    Targeted Oncology 17762596 2022, The Author(s)
    Targeted Oncology 17762596 2022, Incyte Corporation
    Targeted Oncology 17762596 The Author(s) 2024
    Unknown (1776-2596) 1776-2596 Unknown